Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$28.09 USD

28.09
46,845,401

-0.21 (-0.74%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $28.11 +0.02 (0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (58 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Pfizer (PFE) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Pfizer (PFE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Johnson & Johnson (JNJ) Q4 Earnings Top Estimates

Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 5.86% and 0.22%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Concert (CNCE) Stock Up 17% Last Week on Sun Pharma Buyout Offer

Concert Pharmaceuticals (CNCE) enters into a definitive agreement to be acquired by India-based Sun Pharmaceutical for $576 million. Stock up 17% in the previous week.

Pfizer (PFE) Stock Moves -0.09%: What You Should Know

In the latest trading session, Pfizer (PFE) closed at $44.96, marking a -0.09% move from the previous day.

Novavax (NVAX) Gets Nod for COVID-19 Booster Jab in South Korea

Novavax's (NVAX) COVID-19 vaccine gets approval in South Korea as a booster dose in adults 18 years and older.

The Zacks Analyst Blog Highlights Pfizer, Abbott Laboratories, Union Pacific Corporation, Citigroup and Intuitive Surgical.

Pfizer, Abbott Laboratories, Union Pacific Corporation, Citigroup and Intuitive Surgical are part of the Zacks top Analyst Blog.

J&J (JNJ) Discontinues HIV Vaccine Phase III Mosaico Study

J&J (JNJ) discontinues phase III study on its investigational HIV vaccine regimen, which shows that the candidate lacks efficacy in preventing HIV.

Sheraz Mian headshot

Top Analyst Reports for Pfizer, Abbott Laboratories & Union Pacific

Today's Research Daily features new research reports on 16 major stocks, including Pfizer Inc. (PFE), Abbott Laboratories (ABT) and Union Pacific Corporation (UNP).

Moderna (MRNA) Up on Upbeat Data From Phase III Study on RSV Jab

Data from a late-stage study showed that Moderna's (MRNA) RSV vaccine was 83.7% effective at preventing at least two symptoms in adults aged 60 and older.

3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income

The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?

Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know

Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Is Invesco Dynamic Large Cap Value ETF (PWV) a Strong ETF Right Now?

Smart Beta ETF report for PWV

Valneva (VALN) Stock Down 61.5% in the Past Year: Here's Why

Valneva's (VALN) COVID-19 vaccine looks promising, but the European Commission's revised advance purchase agreement jeopardizes its COVID-19 vaccine program.

Deciphera (DCPH) Rises 70% in the Past 6 Months: Here's Why

Deciphera's (DCPH) Qinlock, approved for treating advanced gastrointestinal stromal tumors, has seen strong uptake since its approval. The recent restructuring initiative is saving costs.

Should Schwab U.S. Dividend Equity ETF (SCHD) Be on Your Investing Radar?

Style Box ETF report for SCHD

Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know

Pfizer (PFE) closed at $47.62 in the latest trading session, marking a -1.59% move from the prior day.

Novavax (NVAX) Names John Jacobs as New CEO, Shares Rise

Novavax (NVAX) appoints John C. Jacobs as its new president and chief executive officer, effective Jan 23, 2023.

FDA Accepts Pfizer's (PFE) sBLA Filing for Pneumococcal Jab

The FDA grants priority review to Pfizer's (PFE) filing seeking label expansion of its pneumococcal 20-valent conjugate vaccine in infants and children. A decision is expected by this April.

Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It

Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Deciphera (DCPH) Issues Strategic & Corporate Outlook for 2023

Deciphera (DCPH) provides a strategic outlook and planned corporate milestones for 2023. The company also posts preliminary fourth-quarter and 2022 revenues.

Why Pfizer (PFE) Could Beat Earnings Estimates Again

Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Pfizer (PFE) Gains As Market Dips: What You Should Know

In the latest trading session, Pfizer (PFE) closed at $51.26, marking a +0.04% move from the previous day.